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but differed in the number of antigen-spe-
cific T cells generated (Figure 1). Alum
induced the fewest number of T cells,
whereas MPL induced the most. Some-
what surprisingly, all adjuvants, regard-
less of TLR ligation, were able to induce
the clonal expansion of PCC-specific T
cells. However, important differences be-
tween adjuvants were revealed when the
avidity of the expanded T cells was char-
acterized by either the number of pre-
ferred features of the CDR3 or tetramer
binding. Alum, IFA, and CFA promoted
PCC-specific T cell clones that were of
lower avidity, whereas CpG and MPL
preferentially stimulated the higher avidity
T cell clones (Figure 1). Thus, the inclusion
of TLR agonists into the adjuvant formula-
tions directly correlated with increased
accumulation of higher-avidity T cells. In-
terestingly, the clonal selection of PCC-
specific T cells was independent of anti-
gen dose. This implies that there does
not appear to be interclonal competition
among CD4+ T cells for antigen, in con-
trast to what has been shown for CD8+ T
cells.
In summary, the system described by
Malherbe et al. (2008) represents an im-
portant step forward in quantifying the pa-
rameters of T cell responses that may cor-
relate with vaccine efficacy. It will now be
critical to determine whether these five
adjuvants elicit similar responses with
different model antigens. With the clear
demonstration that adjuvant formulation
can substantially modify the number and
avidity of antigen-specific T cells selected
in response to soluble-protein immuniza-
tion, we can investigate the effect of these
different populations of T cells on the de-
velopment of T cell memory and effective
pathogen responses. For instance, this
system could be employed to determine
whether higher-avidity T cells result in
improved development of T cell memory.
Furthermore, this system could be ex-
ploited to clarify mechanisms by which
adjuvants operate. Open questions in-
clude whether adjuvants are acting upon
T cells, antigen-presenting cells, or both.
Also, although this study showed that
adjuvants that are TLR ligands induced
higher-avidity T cell responses, it is not
yet clear that TLR-agonist adjuvants will
markedly improve vaccine efficacy. How-
ever, the findings of Malherbe et al. (2008)
represent one more step along the road
toward the development of effective
subunit-based vaccines.
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In this issue of Immunity, Miller et al. (2008) usemultiple independent techniques to demonstrate that antiviral
T cell responses after acute human infection are much larger than previously realized.Several groups have demonstrated that
antiviral CD8+ T cell responses in mice
can be enormous—with virus-specific T
cells representing up to 50%–80% of the
total CD8+ T cell population at the peak
of the immune response and/or the ana-
tomical site of infection (Murali-Krishna
et al., 1998). Such dramatic T cell re-
sponses were thought to be associated
withonlya fewselect pathogens (e.g., lym-
phocytic choriomeningitis virus; LCMV) or
perhaps related to the large virus doses604 Immunity 28, May 2008 ª2008 Elsevier Iand invasive routes of infection (e.g., intra-
peritoneal administration) that are often
used during experimental infection of ani-
mals. Acute viral infection of humans, on
the other hand, was thought to result in
a much smaller CD8+ T cell response.
However, as described in this issue of
Immunity, Miller et al. (2008) provide
compelling evidence indicating that the
magnitude of CD8+ T cell responses iden-
tified in humans after acute viral infection
might indeed rival the magnitude of antivi-nc.ral T cell responses observed in experi-
mental animal models.
Miller et al. (2008) analyzed virus-spe-
cific CD8+ T cell responses against two
unrelated viruses: yellow fever virus
(YFV) and vaccinia virus (VV). Although
both YFV and VV represent acute viral in-
fections, they differ in many ways. YFV is
a small RNA virus that encodes just ten
genes, and following subcutaneous inoc-
ulation, it spreads systemically, resulting
inn a transient viremia in the infected
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encoding 200 genes, and after transcu-
taneous inoculation, it rarely spreads
systemically and the viral infection is lo-
calized mainly to the inoculation site on
the skin. If the authors had studied only
one virus, then one might have argued
that the ensuing results could be specific
to just that one model. However, similar
results were observed with two different
viruses, lending credence to their asser-
tion that the magnitude of the virus-spe-
cific T cell response might be larger than
previously thought. Comparison of the
antiviral T cell responses in both model
systems side-by-side and the finding of
similar outcomeswithin both systems (an-
tiviral T cell responses potentially as high
as 12%–40%) suggest that strong T cell
activation following acute viral infection
might be the rule instead of the exception.
Miller et al. (2008) used a combination
of three main approaches to T cell quanti-
tation: peptide-MHC tetramer staining, in-
tracellular cytokine staining after in vitro
stimulation, and phenotypic analysis of
activation markers (Figure 1). Each of
these approaches has advantages and
drawbacks. Staining of CD8+ T cells with
their cognate peptide antigen in the con-
text of fluorochrome-labeled MHC Class
I molecules provides direct evidence of
antigen specificity but does not necessar-
ily demonstrate function. On the other
hand, phenotypic analysis of peptide-
MHC tetramer-positive T cells does
provide information about the native and
unmanipulated in vivo phenotype of the
cells. Moreover, some functions, such as
granzyme and perforin expression, are
probably best measured by staining of
tetramer-positive T cells, but this still rep-
resents only indirect evidence of potential
lytic activity. Other drawbacks associated
with peptide-MHC tetramer staining are
that it requires a priori knowledge of pep-
tide specificity and that it only measures
one peptide-specific T cell population at
a time. If the peptide-MHC combination
of interest happens to be a subdominant
epitope, then the majority of the T cell
response could go unmeasured (and, un-
fortunately, unnoticed) by this approach.
This might explain why tetramer staining,
although highly specific, provided the
lowest sensitivity in terms of detection of
the total number of VV-specific T cells
(0.2%–0.5% MHC Class I tetramer+ at
the peak of the immune response) in theFigure 1. Virus-Induced T Cell Responses During Acute Infection
This figure illustrates the concept that current methods for the detection of virus-specific T cells might rep-
resent a substantial underestimate of their true frequency during the course of an acute viral infection. The
MHCClass I tetramer-positive population represents T cells that bind a single peptide-specificMHCClass
I tetramer, such as the HLA-A2- VVCLT tetramer used in the study by Miller et al. (2008). The cytokine-pos-
itive population represents cells that produce cytokines such as IFN-g after stimulation with live virus or
overlapping 15-mer peptide pools followed by intracellular cytokine staining (ICCS) directly ex vivo. The
activated phenotype population represents either the CD38+HLA-DR+ subset or the Ki-67+Bcl-2 subset,
which are shown by Miller et al. (2008) to be roughly equivalent in magnitude. The data presented in this
study indicate that methods such as ICCS might identify only about one-third of the total human CD8+ T
cell response elicited by an acute viral infection.study by Miller et al. (2008). Even so, it
provided kinetic data that was strikingly
similar to a previous study showing that
the peak VV-specific CD8+ T cell re-
sponse occurred at 14 days postinfection
and then declined rapidly thereafter
(Terajima et al., 2003).
Intracellular cytokine staining (ICCS)
provides a direct functional readout via
the production and detection of antiviral
cytokines. If the virus of interest can be
used for direct stimulation, then one may
theoretically stimulate the total peptide-
specific response—as long as both dom-
inant and subdominant peptides are
similarly processed and presented by
the infected APC used in the assay. This
is the method of choice for large viruses
such as VV, because this virus preferen-
tially infects human monocytes and pres-
ents peptides to both CD4+ and CD8+ T
cell populations (Dasgupta et al., 2007).
Alternatively, pools of overlapping pep-
tides can be used to stimulate antiviral T
cell responses directly ex vivo, and with
small viruses such as YFV, this may be
the preferred approach for measurement
of the total virus-specific T cell response.
Using direct ex vivo ICCS assays, Miller
et al. (2008) show that antiviral CD8+ T
cell responses against both YFV and VVImmappear to peak around 14 days after in-
fection, with virus-specific IFNg+ T cell
frequencies reaching approximately 2%
and 3%–14% of the total CD8+ T cell
response for YFV and VV, respectively.
An intriguing development noted in the
study byMiller et al. (2008) is that it is pos-
sible that MHC Class I tetramer staining
and ICCS might both be measuring only
a fraction of the total virus-specific T cell
response. The authors examined the ex-
pression of phenotypic markers of T cell
activation, CD38 and HLA-DR, the prolif-
eration marker, Ki-67, as well as the anti-
apoptotic protein, Bcl-2. They concluded
that the total activated T cell response in-
duced by acute viral infection might be up
to 3-fold higher than the total T cell
response that is measured by ICCS. The
basis for this assumption is provided by
the observation that MHC Class I tetra-
mer+ VV-specific T cells are uniformly
CD38+HLA-DR+ and Ki-67+Bcl-2– at the
peak of the T cell response. In contrast,
MHC Class I tetramer+ T cells specific for
Epstein-Barr virus or influenza virus re-
mained negative for these phenotypic
marker combinations during the effector
phase that follows either YFV or VV infec-
tion—indicating that bystander activation
of preexisting memory T cells of otherunity 28, May 2008 ª2008 Elsevier Inc. 605
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ics of T cells expressing this activated
phenotype also closely match those of
the antigen-specific T cells measured by
ICCS as well as by MHC Class I tetramer
staining. However, YFV-specific and VV-
specific memory T cells soon lose the
CD38+HLA-DR+ and the Ki-67+Bcl-2–
phenotype, and therefore these markers
are only useful for approximating the total
T cell response elicited during the acute
phase of infection. Nonetheless, this pro-
vides food for thought in terms of the real-
ization that the antiviral T cell response
might be larger thanwhatwe canmeasure
through current functional assays such as
IFNg-based ICCS.
There are several questions that remain
unanswered with regard to the study by
Miller et al. (2008). For instance, if intracel-
lular IFNg production ‘‘tags’’ only one-
third of the total virus-specific T cell
response (as measured by an activated
CD38+HLA-DR+ or Ki-67+Bcl-2– T cell
phenotype), then what cytokines, if any,
do the other two-thirds of the CD8+ T cells
make following stimulation with antigen?
Does this mean that the majority of the T
cell response represents non-IFNg pro-
ducers in humans, or is it possible that
our approaches to in vitro stimulation
require further optimization? Others have
commented that because of the multi-B Young Again
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Hanna et al. (2008) report in a recen
mature B cells back to pluripotent s
The stem cell field was stunned two years
ago when Takahashi and Yamanaka dem-
onstrated that the transcription factors
Oct4, Sox2, Klf4, and c-Myc are capable
of reprogramming fibroblasts into what
was termed induced pluripotent stem
(iPS) cells. iPS cells closely resemble
606 Immunity 28, May 2008 ª2008 Elsevierfunctional nature of heterologous T cell
populations, measurement of any one
cytokine alone could lead to a lower,
more-conservative estimate of the total
antigen-specific T cell response (Seder
et al., 2008). With this in mind, it will be in-
teresting to learn the full spectrum of hu-
man cytokine production profiles that
are elicited following various acute viral
infections in both the effector and the
memory phases of the immune response.
On the basis of the results of the study
by Miller et al. (2008), it appears clear
that virus-specific T cell responses follow-
ing acute infection in humans are larger
than expected and vary substantially de-
pending on the efficiency of the technique
used to measure them. Importantly, both
YFV and VV represent viruses that infect
the host through a peripheral route. It will
be interesting to learn whether respiratory
viral infections such as influenza virus or
respiratory syncytial virus are also capa-
ble of eliciting large frequencies of virus-
specific CD8+ T cells in the bloodstream.
Further in-depth analysis of virus-specific
T cell kinetics will be important, given that
it appears that CD8+ T cell responses de-
cay very rapidly in the short term (i.e., the
first weeks after infection) compared to
the long-term (i.e., months or years after
vaccination [Co et al., 2002; Crotty et al.,
2003; Hammarlund et al., 2003]). Analysis2,*
guader 88, E-08003 Barcelona, Spain
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t issue of Cell that a defined set of t
tem cells.
embryonic stem (ES) cells in their cellular
phenotype and gene-expression profile
(Takahashi andYamanaka, 2006) andcon-
tribute to the germline when transplanted
into blastocysts (Okita et al., 2007; Wernig
et al., 2007). Because of the low reprog-
ramming efficiency, it remained, however,
Inc.of T cell responses following booster
vaccination or re-infection will be another
interesting avenue of investigation. To-
gether, these studies will lead to a better
understanding of antiviral T cell respon-
ses and maintenance of immunological
memory in humans.
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